TGF-β signaling in tumor suppression and cancer progression

Nature Genetics

Volumn 29, Issue 2, 2001, Pages 117-129

  Derynck, Rik ^a   Akhurst, Rosemary J ^b   Balmain, Allan ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FAS LIGAND; RAS PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; B LYMPHOCYTE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; ENZYME REGULATION; GENE EXPRESSION REGULATION; HUMAN; IMMUNOMODULATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; DISEASE PROGRESSION; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0034785348     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/ng1001-117     Document Type: Review

References (313)

1. TGF-β signal transduction
2. Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor receptor by human tumors
3. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17β-estradiol or v-Ha-ras oncogene
4. Transforming growth factor-β: Latent forms, binding proteins and receptors
5. Latent transforming growth factor-β: Structural features and mechanisms of activation
6. The latent transforming growth factor β binding protein (LTBP) family
7. Extracellular matrix-associated transforming growth factor-β: Role in cancer cell growth and invasion
8. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: Activation of a latent transforming growth factor-β1-like molecule by plasmin during co-culture
9. Mechanism of activation of latent recombinant transforming growth factor β 1 by plasmin
10. The urokinase-type plasminogen activator system in cancer metastasis: A review
11. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis
12. Matrix metalloproteinases in tumor invasion and metastasis
13. Proteases in invasion: Matrix metalloproteinases
14. Thrombospondin causes activation of latent transforming growth factor-β secreted by endothelial cells by a novel mechanism
15. Thrombospondin-1 is a major activator of TGF-β 1 in vivo
16. The integrin αvβ6 binds and activates latent TGF β1: A mechanism for regulating pulmonary inflammation and fibrosis
17. TGF-β receptor signaling
18. Specificity, diversity, and regulation in TGF-β superfamily signaling
19. Signaling of transforming growth factor-β family members through Smad proteins
20. How cells read TGF-β signals
21. TGF-β signaling in growth control, cancer, and heritable disorders
22. TGF-β signaling by Smad proteins
23. The immunophilin FKBP12 functions as a common inhibitor of the TGF-β family type I receptors
24. Mechanism of TGF-β receptor inhibition by FKBP 12
25. FKBP12 is a negative regulator of transforming growth factor-β receptor internalization
26. FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle
27. A WD-domain protein that is associated with and phosphorylated by the type II TGF-β receptor
28. The type II transforming growth factor (TGF)-β receptorinteracting protein TRIP-1 acts as a modulator of the TGF-β response
29. Physical and functional interactions between type I transforming growth factor β receptors and Bα, a WD- 40 repeat subunit of phosphatase 2A
30. Identification of STRAP, a novel WD domain protein in transforming growth factor-β signaling
31. STRAP and Smad7 synergize in the inhibition of transforming growth factor β signaling
32. TGF-β inhibits p70 S6 kinase via protein phosphatase 2A to induce G1 arrest
33. Smads: Transcriptional activators of TGF-β responses
34. Transcriptional control by the TGF-β/Smad signaling system
35. Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor β growth arrest program
36. TGF-β-induced repression of CBFA 1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation
37. Smad3 represses androgen receptor-mediated transcription
38. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-β-induced transcription
39. Smads bind directly to the Jun family of AP-1 transcription factors
40. Structural and functional characterization of the transforming growth factor-β-induced Smad3/c-Jun transcriptional cooperativity
41. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-β signaling
42. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-β-induced gene expression
43. Transcriptional regulation of the transforming growth factor-β-inducible mouse germ line Igα constant region gene by functional cooperation of Smad, CREB, and AML family members
44. Synergistic cooperation of TFE3 and Smad proteins in TGF-β-induced transcription of the plasminogen activator inhibitor-1 gene
45. Specificity in transforming growth factor β-induced transcription of the plasminogen activator inhibitor-1 gene: Interactions of promoter DNA, transcription factor μE 3, and Smad proteins
46. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Cα promoter
47. Smad and AML proteins synergistically confer transforming growth factor β1 responsiveness to human germ-line 1gα genes
48. Convergence of transforming growth factor-β and vitamin D signaling pathways on SMAD transcriptional coactivators
49. Glucocorticoid receptor inhibits transforming growth factor-β signaling by directly targeting the transcriptional activation function of Smad3
50. From transforming growth factor-β signaling to androgen action: Identification of Smad3 as an androgen receptor coregulator in prostate cancer cells
51. Synergistic signaling in fetal brain by STAT3-Smadl complex bridged by p300
52. TGF-β-stimulated cooperation of Smad proteins with the coactivators CBP/p300
53. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for Smad3 in TGF-βinduced transcriptional activation
54. TGF-β-induced phosphorylation of Smad3 regulates its interaction with coactivator p300/CREB-binding protein
55. Tumor suppressor Smad4 is a transforming growth factor βinducible DNA binding protein
56. Human Smad3 and Smad4 are sequence-specific transcription activators
57. Direct binding of Smad3 and Smad4 to critical TGF β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene
58. Crystal structure of a Smad MH1 domain bound to DNA: Insights on DNA binding in TGF-β signaling
59. Transcriptional activating activity of 5mad4: Roles of SMAD hetero-oligomerization and enhancement by an associating transactivator
60. The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors
61. The oncoprotein Evi-1 represses TGF-β signalling by inhibiting Smad3
62. The Ski oncoprotein interacts with the Smad proteins to repress TGFβ signaling
63. C-Ski acts as a transcriptional co-repressor in transforming growth factor-β signaling through interaction with Smads
64. Negative feedback regulation of TGF-β signaling by the SnoN oncoprotein
65. A Smad transcriptional corepressor
66. A novel Smad nuclear interacting protein, SNIP1, suppresses p300-dependent TGF-β signal transduction
67. SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5'-CACCT sequences in candidate target genes
68. Regulation of Smad signalling by protein associations and signalling crosstalk
69. Signaling inputs converge on nuclear effectors in TGF-β signaling
70. TGF-β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway
71. Smad3-Smad4 and AP-1 complexes synergize in transcriptional activation of the c-Jun promoter by transforming growth factor β
72. Requirement of Ras/MAPK pathway activation by transforming growth factor β for transforming growth factor β1 production in a Smad-dependent pathway
73. Interdependent SMAD and JNK signaling in transforming growth factor-β-mediated transcription
74. Requirements for transforming growth factor-β regulation of the pro-α 2(1) collagen and plasminogen activator inhibitor-1 promoters
75. An AP-1 binding sequence is essential for regulation of the human α2(1) collagen (COL1A2) promoter activity by transforming growth factor-β
76. Potentiation of Smad transactivation by Jun proteins during a combined treatment with epidermal growth factor and transforming growth factor-β in rat hepatocytes. Role of phosphatidylinositol 3-kinase-induced AP-1 activation
77. Transcriptional activation of a conserved sequence element by Ras requires a nuclear factor distinct from c-Fos or c-Jun
78. Characterization of the mouse transforming growth factor-β1 promoter and activation by the Ha-ras oncogene
79. Transforming growth factor β1 positively regulates its own expression in normal and transformed cells
80. Altered regulation of TGF-β1 and TGF-α in primary keratinocytes and papillomas expressing v-Ha-ras
81. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP- 1 sequences
82. Transcriptional activation of the matrix metalloproteinase-9 gene in an H-ras and v-myc transformed rat embryo cell line
83. Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells
84. A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras
85. Smad4/DPC4 silencing and hyperactive Ras jointly disrupt transforming growth factor-β antiproliferative responses in colon cancer cells
86. Raf induces TGFβ production while blocking its apoptotic but not invasive responses: A mechanism leading to increased malignancy in epithelial cells
87. TGF-β1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells
88. Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-β and Wnt pathways
89. Interaction between Wnt and TGF-β signalling pathways during formation of Spemann's organizer
90. Human T-cell leukemia virus type I oncoprotein Tax represses Smad-dependent transforming growth factor β signaling through interaction with CREB-binding protein/p300
91. The hepatitis B virus encoded oncoprotein pX amplifies TGF-β family signaling through direct interaction with Smad4: Potential mechanism of hepatitis B virus-induced liver fibrosis
92. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type β signaling
93. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-β family members
94. Inhibition of transforming growth factorβ/SMAD signalling by the interferon-γ/STAT pathway
95. A mechanism of suppression of TGF-β/SMAD signaling by NFκB/ReIA
96. Activation of p21Ras by transforming growth factor β in epithelial cells
97. Transforming growth factor β activation of p44MAPK in proliferating cultures of epithelial cells
98. Role of Ras and MAPKs in TGFβ signaling
99. Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction
100. TAK1 mediates the ceramide signaling to stress-activated protein kinase/c-Jun N-terminal kinase
101. Role of TAK 1 and TAB1 in BMP signaling in early Xenopus development
102. The kinase TAK1 can activate the NIK-lκB as well as the MAP kinase cascade in the IL-1 signalling pathway
103. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway
104. Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism
105. RhoB is stabilized by transforming growth factor β and antagonizes transcriptional activation
106. Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor β
107. Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation
108. TGF-β stimulation and inhibition of cell proliferation: New mechanistic insights
109. INK4B is a potential effector of TGF-β-induced cell cycle arrest
110. Kip/CIP and INK4 CDK inhibitors cooperate to induce cell cycle arrest in response to TGF-β
111. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism
112. INK4B-CDK4 complexes, and inhibits cyclin D1-CDK 4 association in human mammary epithelial cells
113. INK4B transcription in response to TGF-β
114. Waf1/CIP1 regulation by transforming growth factor-β
115. TGF-β inhibition of Cdk4 synthesis is linked to cell cycle arrest
116. p53-dependent repression of CDK4 translation in TGF-β-induced G1 cell-cycle arrest
117. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15
118. E2F and histone deacetylase mediate transforming growth factor β repression of cdc 25A during keratinocyte cell cycle arrest
119. Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor β1
120. INK4a G1 arrest pathway
121. CIP1 by c-Myc in overcoming transforming growth factor β-induced cell-cycle arrest
122. INK4b expression by Myc through association with Miz-1
123. INK4b
124. Cdc25 cell-cycle phosphatase as a target of c-myc
125. Involvement of Myc activity in a G1/S-promoting mechanism parallel to the pRb/E 2F pathway
126. Coordinated regulation of apoptosis and cell proliferation by transforming growth factor β 1 in cultured uterine epithelial cells
127. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor β1
128. The novel primary response gene MyD118 and the protooncogenes myb, myc, and bcl-2 modulate transforming growth factor β1-induced apoptosis of myeloid leukemia cells
129. Characterization of transforming growth factor-β1 induced apoptosis in normal human B cells and lymphoma B cell lines
130. Smad7 mediates apoptosis induced by transforming growth factor β in prostatic carcinoma cells
131. A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif
132. Smad7 is induced by CD40 and protects WEHI 231 B-lymphocytes from transforming growth factor-β-induced growth inhibition and apoptosis
133. TGF-βinduced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation
134. Induction of apoptosis by DPC4, a transcriptional factor regulated by transforming growth factor-β through stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) signaling pathway
135. Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-β in human normal lung epithelial cells
136. G1 cell cycle arrest and apoptosis induction by nuclear Smad4/Dpc4: Phenotypes reversed by a tumorigenic mutation
137. Critical role of Smads and AP-1 complex in transforming growth factor-β-dependent apoptosis
138. Smad7 inhibits the survival nuclear factor κB and potentiates apoptosis in epithelial cells
139. Smad7 is an activin-inducible inhibitor of activin-induced growth arrest and apoptosis in mouse B cells
140. Transforming growth factor-β-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-XL down regulation
141. L blocks TGF-β1induced apoptosis by inhibiting cytochrome C release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells
142. Activation of caspase-8 in transforming growth factor-β-induced apoptosis of human hepatoma cells
143. Involvement of caspase family proteases in transforming growth factor-β-induced apoptosis
144. Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor β1-induced apoptosis
145. Suppression of transforming growth factor-β-induced apoptosis through a phosphatidylinositol 3-kinase/Aktdependent pathway
146. Interleukin-6 inhibits transforming growth factor-β-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways
147. Hepatitis B virus X protein inhibits transforming growth factor-β-induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway
148. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability
149. A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability
150. Genomic structure of the transforming growth factor β type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers
151. Genetic changes in the transforming growth factor β (TGF-β) type II receptor gene in human gastric cancer cells: Correlation with sensitivity to growth inhibition by TGF-β
152. Microsatellite instability-associated mutations associate preferentially with the intestinal type of primary gastric carcinomas in a high-risk population
153. Mutations of the transforming growth factor β type II receptor gene and microsatellite instability in gastric cancer
154. Microsatellite instability and mutated type II transforming growth factor-β receptor gene in gliomas
155. Mutation analysis of the transforming growth factor β type II receptor in sporadic human cancers of the pancreas, liver, and breast
156. Mutation analysis of transforming growth factor 13 type II receptor, Smad2, and Smad4 in hepatocellular carcinoma
157. Gene mutation of transforming growth factor β 1 type II receptor in hepatocellular carcinoma
158. Analyses of microsatellite instability and the transforming growth factor-β receptor type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features
159. Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers
160. TGF-β and cancer
161. Transforming growth factor β type I receptor kinase mutant associated with metastatic breast cancer
162. Transforming growth factor-β receptor type I gene is frequently mutated in ovarian carcinomas
163. Genetic alterations of the transforming growth factor β receptor genes in pancreatic and biliary adenocarcinomas
164. A deletion in the gene for transforming growth factor β type I receptor abolishes growth regulation by transforming growth factor β in a cutaneous T-cell lymphoma
165. Analysis of specific gene mutations in the transforming growth factor-β signal transduction pathway in human ovarian cancer
166. A dominant inhibitory mutant of the type II transforming growth factor β receptor in the malignant progression of a cutaneous T-cell lymphoma
167. Down-regulation of protein and mRNA expression for transforming growth factor-β (TGF-β1) type I and type II receptors in human prostate cancer
168. Consistent loss of functional transforming growth factor β receptor expression in murine plasmacytomas
169. Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis
170. Inhibition of growth by transforming growth factor-β following fusion of two nonresponsive human carcinoma cell lines. Implication of the type II receptor in growth inhibitory responses
171. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-β activities
172. A glycosylation-deficient endothelial cell mutant with modified responses to transforming growth factor-β and other growth inhibitory cytokines: Evidence for multiple growth inhibitory signal transduction pathways
173. Transforming growth factor-β (TGF-β)induced down-regulation of cyclin A expression requires a functional TGF-β receptor complex. Characterization of chimeric and truncated type I and type II receptors
174. Signaling activity of transforming growth factor β type II receptors lacking specific domains in the cytoplasmic region
175. Transforming growth factor β is essential for spindle cell conversion of mouse skin carcinoma in vivo: Implications for tumor invasion
176. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF- 7 cells
177. Demonstration that mutation of the type II transforming growth factor β receptor inactivates its tumor suppressor activity in replication errorpositive colon carcinoma cells
178. Overexpression of transforming growth factor β-type II receptor reduces tumorigenicity and metastastic potential of K-ras-transformed thyroid cells
179. TGFβ 1 inhibits the formation of benign skin tumours but enhances progression to invasive spindle cell carcinomas in transgenic mice
180. Development of gene-switch transgenic mice that inducibly express transforming growth factor β1 in the epidermis
181. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene
182. Blocking transforming growth factor β signaling in transgenic epidermis accelerates chemical carcinogenesis: A mechanism associated with increased angiogenesis
183. Transforming growth factor β1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis
184. Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency
185. Loss of responsiveness to transforming growth factor β induces malignant transformation of nontumorigenic rat prostate epithelial cells
186. Differential expression of transforming growth factor β receptors in human pancreatic adenocarcinoma
187. Alteration of cell growth and morphology by overexpression of transforming growth factor β type II receptor in human lung adenocarcinoma cells
188. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor β type II receptor expression in human breast cancer cells
189. Microsatellite instability and the role of hMSH 2 in sporadic colorectal cancer
190. TGF-β signaling and cancer: Structural and functional consequences of mutations in Smads
191. DPC 4, a candidate tumor suppressor gene at human chromosome 18q21. 1
192. Haploid loss of the tumor suppressor Smad4/Dpc 4 initiates gastric polyposis and cancer in mice
193. Allelic loss is often the first hit in the biallelic inactivation of the p 53 and DPC4 genes during pancreatic carcinogenesis
194. Mutations in the SMAD4/DPC 4 gene in juvenile polyposis
195. MADR2 maps to 18q21 and encodes a TGFβ-regulated MADrelated protein that is functionally mutated in colorectal carcinoma
196. Somatic alterations of the SMAD-2 gene in human colorectal cancers
197. Smad2 and Smad4 gene mutations in hepatocellular carcinoma
198. Somatic alterations of the DPC 4 and Madr2 genes in colorectal cancers and relationship to metastasis
199. The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer
200. The tumor suppressor Smad4/DPC 4 as a central mediator of Smad function
201. A single missense mutant of Smad3 inhibits activation of both Smad2 and Smad3, and has a dominant negative effect on TGF-β signals
202. Mechanism for mutational inactivation of the tumor suppressor Smad2
203. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor β signaling by targeting Smads to the ubiquitin-proteasome pathway
204. Dpc4 transcriptional activation and dysfunction in cancer cells
205. Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4
206. Evidence that Smad2 is a tumor suppressor implicated in the control of cellular invasion
207. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes
208. Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice
209. Smad3 mutant mice develop metastatic colorectal cancer
210. Targeted disruption of Smad3 reveals an essential role in transforming growth factor β-mediated signal transduction
211. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β
212. Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor β-related signaling
213. Transforming growth factor-β responsiveness in DPC4/SMAD4-null cancer cells
214. Transforming growth factor-β-induced growth inhibition in a Smad 4 mutant colon adenoma cell line
215. Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas
216. Expression of the c-ski protooncogene in human melanoma cell lines
217. Repression of the gene encoding the TGF-β type II receptor is a major target of the EWS-FLl 1 oncoprotein
218. Cellular activation of latent transforming growth factor β requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor
219. M6P/IGF 2R is mutated in squamous cell carcinoma of the lung
220. M6P/IGF 2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity
221. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis
222. Regulation of mannose 6-phosphate/insulin-like growth factor-II receptors and transforming growth factor β during liver tumor promotion with phenobarbital
223. Epithelial cell plasticity in development and tumor progression
224. Spindle cell carcinoma: Ultrastructural evidence of squamous origin and collagen production by the tumor cells
225. Epithelioid sarcoma: A clinicopathologic and prognostic study of 26 cases
226. Progression of squamous carcinoma cells to spindle carcinoma of the mouse skin is associated with an imbalance of H-ras alleles on chromosome 7
227. The conversion of mouse skin squamous cell carcinomas to spindle cell carcinomas is a recessive event
228. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis
229. Epithelial-mesenchymal cell transformation in the embryonic heart can be mediated, in part, by transforming growth factor β
230. Requirement of type III TGF-β receptor for endocardial cell transformation in the heart
231. Transforming growth factor-β 3 is required for secondary palate fusion
232. Abnormal lung development and cleft palate in mice lacking TGF-β3 indicates defects of epithelial-mesenchymal interaction
233. Growth factors specifically alter hair follicle cell proliferation and collagenolytic activity alone or in combination
234. Vertebrate mesendoderm induction and patterning
235. TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: Involvement of type I receptors
236. Effects of transforming growth factor β on growth of human mammary epithelial cells in culture. In vitro
237. TGF-β type I receptor/ALK- 5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells
238. Chronic exposure of cultured transfected mouse epidermal cells to TGFβ1 induces an epithelial-mesenchymal transdifferentiation and a spindle tumoral phenotype
239. Epithelial-mesenchymal transformation of a newly established cell line from ovarian adenosarcoma by transforming growth factor-β1
240. Autocrine TGF-β-regulated expression of adhesion receptors and integrin-linked kinase in HT-144 melanoma cells correlates with their metastatic phenotype
241. Urokinase expression and binding activity associated with the transforming growth factor β1-induced migratory and invasive phenotype of mouse epidermal keratinocytes
242. Enhanced tumorigenicity and invasion metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network
243. Neurofibromin modulation of ras activity is required for normal endocardial-mesenchymal transformation in the developing heart
244. Cyclosporine induces cancer progression by a cell-autonomous mechanism
245. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development
246. The hallmarks of cancer
247. Transforming growth factor type β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro
248. Phenotypic modulation of endothelial cells by transforming growth factor-β depends upon the composition and organization of the extracellular matrix
249. Transforming growth factor β1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane
250. Basic fibroblast growth factor and transforming growth factor β1: Synergistic mediators of angiogenesis in vitro
251. Inhibition of capillary morphogenesis and associated apoptosis by dominant negative mutant transforming growth factor-β receptors
252. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17β-estradiol or v-Ha-ras oncogene
253. TGF-β receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis
254. Abnormal angiogenesis but intact hematopoietic potential in TGF-β type I receptor-deficient mice
255. Activin receptor-like kinase 1 modulates transforming growth factor-β1 signaling in the regulation of angiogenesis
256. Defective angiogenesis in mice lacking endoglin
257. Endoglin, an ancillary TGFβ receptor, is required for extraembryonic angiogenesis and plays a key role in heart development
258. Smad5 knockout mice die at mid-gestation due to multiple embryonic and extraembryonic defects
259. Angiogenesis defects and mesenchymal apoptosis in mice lacking Smad 5
260. Excessive production of transforming growth-factor β1 can play an important role in the development of tumorigenesis by its action for angiogenesis: Validity of neutralizing antibodies to block tumor growth
261. Role of interleukin 10 and transforming growth factor β 1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodefidency mice
262. Transforming growth factor β1 is a target for the von HippelLindau tumor suppressor and a critical growth factor for clear cell renal carcinoma
263. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis
264. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II. Correlations with proliferation and angiogenesis
265. Positive correlation of plasma transforming growth factor-β1 levels with tumor vascularity in hepatocellular carcinoma
266. Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer
267. Transforming growth factor β 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma
268. Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer
269. The expression of transforming growth factor-β1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma
270. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells
271. Macrophage-derived angiogenesis factors
272. Bidirectional regulation of macrophage function by TGF-β
273. Transforming growth factor β modulates the expression of collagenase and metalloproteinase inhibitor
274. Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in human hepatoma cells (HepG2). Up-regulation by interleukin-6 and transforming growth factor β1
275. Involvement of transforming growth factor β 1 in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells
276. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities bytransforming growth factor-β1 in human prostate cancer cell lines
277. Transforming growth factor β 1 acts as an inducer of matrix metalloproteinase expression and activity in human bonemetastasizing cancer cells
278. Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-β in invasive carcinomas
279. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes
280. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins
281. Regulation of immune responses by TGF-β
282. Transforming growth factor-β: Pleiotropic role in the regulation of hematopoiesis
283. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 CDNA escapes immune surveillance
284. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth
285. Transforming growth factor β is an important immunomodulatory protein for human B lymphocytes
286. Transfection of transforming growth factor-β producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytes
287. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor β1
288. The immunoregulatory effects of NK cells: The role of TGF-β and implications for autoimmunity
289. Immunoregulatory role of transforming growth factor β (TGF-β) in development of killer cells: Comparison of active and latent TGF-β1
290. Transforming growth factor β1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice
291. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression
292. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-β
293. Regulation of the proinflamatory effects of Fas ligand (CD95L)
294. Transforming growth factor-β 1 modulates the expression of class II histocompatibility antigens on human cells
295. Transforming growth factor β1 (TGF-β1) controls expression of major histocompatibility genes in the postnatal mouse: Aberrant histocompatibility antigen expression in the pathogenesis of the TGF-β1 null mouse phenotype
296. Autoimmunity associated with TGF-β-deficiency in mice is dependent on MHC class II antigen expression
297. Transforming growth factor-β down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis
298. Immunosuppressive factors: Role in cancer development and progression
299. Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells
300. Transforming growth factor β1 is implicated in the failure of tamoxifen therapy in human breast cancer
301. Induction of transforming growth factor β1 in human breast cancer in vivo following tamoxifen treatment
302. Blockade of transforming growth factor-β signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells
303. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy
304. Antisense oligonucleotides specific for transforming growth factor β2 inhibit the growth of malignant mesothelioma both in vitro and in vivo
305. Expression of an antisense transforming growth factor-β 1 transgene reduces tumorigenicity of EMT6 mammary tumor cells
306. Suppression of TGF-β1 in human gliomas by retroviral gene transfection enhances susceptibility to LAK cells
307. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin
308. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy
309. A soluble transforming growth factor β type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB- 231 cells
310. Negative regulation of transforming growth factor-β by the proteoglycan decorin
311. Decorin gene transfer-mediated suppression of TGF-β synthesis abrogates experimental malignant glioma growth in vivo
312. Modulation of 816 melanoma growth and metastasis by anti-transforming growth factor β antibody and interleukin-2